Disposition of 3854626 shares by Pharmacyte Biotech, Inc. of MyMD Pharmaceuticals at 1.816 subject to Rule 16b-3
| MYMDDelisted Stock | USD 1.82 0.02 1.09% |
About 61% of MyMD Pharmaceuticals' investor base is looking to short. The analysis of current outlook of investing in MyMD Pharmaceuticals suggests that many traders are alarmed regarding MyMD Pharmaceuticals' prospects. The current market sentiment, together with MyMD Pharmaceuticals' historical and current headlines, can help investors time the market. In addition, many technical investors use MyMD Pharmaceuticals stock news signals to limit their universe of possible portfolio assets.
MyMD |
Filed transaction by MyMD Pharmaceuticals 10 Percent Owner. Disposition to the issuer of issuer equity securities pursuant to Rule 16b-3(e)
Read at macroaxis.com
MyMD Pharmaceuticals Fundamental Analysis
We analyze MyMD Pharmaceuticals' financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of MyMD Pharmaceuticals using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of MyMD Pharmaceuticals based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Earnings Per Share
Earnings Per Share Comparative Analysis
MyMD Pharmaceuticals is currently under evaluation in earnings per share category among its peers. Earnings per Share (EPS) denotes the portion of a company's earnings that is allocated to each share of common stock. To calculate Earnings per Share investors will need to take a company's net income, subtract any dividends for preferred stock, and divide it by the number of average outstanding shares. EPS is usually presented in two different ways: basic and diluted. Fully diluted Earnings per Share takes into account effects of warrants, options, and convertible securities and is generally viewed by analysts as a more accurate measure.
MyMD Pharmaceuticals Potential Pair-trading
One of the popular trading techniques among algorithmic traders is to use market-neutral strategies where every trade hedges away some risk. Because there are two separate transactions required, even if one position performs unexpectedly, the other equity can make up some of the losses. Below are some of the equities that can be combined with MyMD Pharmaceuticals stock to make a market-neutral strategy. Peer analysis of MyMD Pharmaceuticals could also be used in its relative valuation, which is a method of valuing MyMD Pharmaceuticals by comparing valuation metrics with similar companies.
Peers
MyMD Pharmaceuticals Related Equities
| UBX | Unity Biotechnology | 4.17 | ||||
| NBY | NovaBay Pharmaceuticals | 3.85 | ||||
| RXRX | Recursion Pharmaceuticals | 3.58 | ||||
| GOVX | GeoVax Labs | 2.26 | ||||
| DSGN | Design Therapeutics | 2.25 | ||||
| BOLT | Bolt Biotherapeutics | 2.00 | ||||
| KZR | Kezar Life | 1.86 | ||||
| NVCT | Nuvectis Pharma | 1.53 | ||||
| XBIO | Xenetic Biosciences | 1.47 | ||||
| REPL | Replimune | 1.30 | ||||
| SRZN | Surrozen | 0.08 | ||||
| AVIR | Atea Pharmaceuticals | 0.31 | ||||
| LGND | Ligand Pharmaceuticals | 0.37 | ||||
| KRON | Kronos Bio | 1.04 | ||||
| PASG | Passage Bio | 1.52 | ||||
| LYEL | Lyell Immunopharma | 1.61 | ||||
| ORIC | Oric Pharmaceuticals | 1.68 | ||||
| GOSS | Gossamer Bio | 2.33 | ||||
| KROS | Keros Therapeutics | 2.39 | ||||
| REVB | Revelation Biosciences | 3.23 | ||||
| LRMR | Larimar Therapeutics | 4.55 | ||||
| LYRA | Lyra Therapeutics | 5.56 |
Check out Correlation Analysis to better understand how to build diversified portfolios. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in population. You can also try the Equity Valuation module to check real value of public entities based on technical and fundamental data.
Other Consideration for investing in MyMD Stock
If you are still planning to invest in MyMD Pharmaceuticals check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the MyMD Pharmaceuticals' history and understand the potential risks before investing.
| Sign In To Macroaxis Sign in to explore Macroaxis' wealth optimization platform and fintech modules | |
| Commodity Channel Use Commodity Channel Index to analyze current equity momentum | |
| My Watchlist Analysis Analyze my current watchlist and to refresh optimization strategy. Macroaxis watchlist is based on self-learning algorithm to remember stocks you like | |
| Stocks Directory Find actively traded stocks across global markets | |
| Global Markets Map Get a quick overview of global market snapshot using zoomable world map. Drill down to check world indexes | |
| Efficient Frontier Plot and analyze your portfolio and positions against risk-return landscape of the market. | |
| FinTech Suite Use AI to screen and filter profitable investment opportunities | |
| Portfolio Manager State of the art Portfolio Manager to monitor and improve performance of your invested capital | |
| Pair Correlation Compare performance and examine fundamental relationship between any two equity instruments |